In the last trading session, 1.0 million Emergent Biosolutions Inc (NYSE:EBS) shares changed hands as the company’s beta touched 1.60. With the company’s per share price at $9.36 changed hands at -$0.05 or -0.53% during last session, the market valuation stood at $507.16M. EBS’s last price was a discount, traded about -61.32% off its 52-week high of $15.10. The share price had its 52-week low at $1.42, which suggests the last value was 84.83% up since then. When we look at Emergent Biosolutions Inc’s average trading volume, we note the 10-day average is 1.17 million shares, with the 3-month average coming to 1.26 million.
Analysts gave the Emergent Biosolutions Inc (EBS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended EBS as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Emergent Biosolutions Inc’s EPS for the current quarter is expected to be -0.5.
Emergent Biosolutions Inc (NYSE:EBS) trade information
Instantly EBS was in red as seen at the end of in last trading. With action -8.86%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -2.09%, with the 5-day performance at -8.86% in the red. However, in the 30-day time frame, Emergent Biosolutions Inc (NYSE:EBS) is 9.22% up. Looking at the short shares, we see there were 7.13 million shares sold at short interest cover period of 6.61 days.
The consensus price target for the stock as assigned by Wall Street analysts is 51.5, meaning bulls need an upside of 81.83% from its current market value. According to analyst projections, EBS’s forecast low is 38 with 65 as the target high. To hit the forecast high, the stock’s price needs a -594.44% plunge from its current level, while the stock would need to soar -305.98% for it to hit the projected low.
Emergent Biosolutions Inc (EBS) estimates and forecasts
Data shows that the Emergent Biosolutions Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -17.24% over the past 6 months, a 89.89% in annual growth rate that is considerably higher than the industry average of 16.70%. Year-over-year growth is forecast to reach 5.18% up from the last financial year.
Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of 254.67M. 1 analysts are of the opinion that Emergent Biosolutions Inc’s revenue for the current quarter will be 279M. The company’s revenue for the corresponding quarters a year ago was 276.6M and 300.4M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -7.93%. The estimates for the next quarter sales put growth at -7.12%.
The 2025 estimates are for Emergent Biosolutions Inc earnings to increase by 86.57%.
EBS Dividends
Emergent Biosolutions Inc is expected to release its next quarterly earnings report in February.
Emergent Biosolutions Inc (NYSE:EBS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.10% of Emergent Biosolutions Inc shares while 59.68% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 60.96%. There are 59.68% institutions holding the Emergent Biosolutions Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 7.3551% of the shares, roughly 3.84 million EBS shares worth $26.18 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 7.0234% or 3.67 million shares worth $25.0 million as of 2024-06-30.
Among Mutual Funds, the top two as of Aug 31, 2024 were Schwab Strategic Tr-Schwab Fundamental U.S. Small Company Index ETF and Avantis U.S. Small Cap Value ETF . With 2.36 shares estimated at $22.09 million under it, the former controlled 4.36% of total outstanding shares. On the other hand, Avantis U.S. Small Cap Value ETF held about 3.10% of the shares, roughly 1.68 shares worth around $15.73 million.
